RGRX (Regenerx Biopharmaceuticals) Accounts Payable: $0.04 Mil (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenerx Biopharmaceuticals Accounts Payable?

Regenerx Biopharmaceuticals RGRX Accounts Payable is $0.04 Mil as of Mar. 2023.

Regenerx Biopharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2023 was $0.04 Mil.

Regenerx Biopharmaceuticals's quarterly Accounts Payable increased from Sep. 2022 ($0.04 Mil) to Dec. 2022 ($0.06 Mil) but then declined from Dec. 2022 ($0.06 Mil) to Mar. 2023 ($0.04 Mil).

Regenerx Biopharmaceuticals's annual Accounts Payable increased from Dec. 2020 ($0.04 Mil) to Dec. 2021 ($0.06 Mil) but then stayed the same from Dec. 2021 ($0.06 Mil) to Dec. 2022 ($0.06 Mil).

Regenerx Biopharmaceuticals Accounts Payable Related Terms

Regenerx Biopharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Regenerx Biopharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerx Biopharmaceuticals Accounts Payable Chart

Regenerx Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.04 0.04 0.06 0.06

Regenerx Biopharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.05 0.04 0.06 0.04

Regenerx Biopharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.04 Mil mean?
Regenerx Biopharmaceuticals (RGRX) has a Accounts Payable of $0.04 Mil as of Mar. 2023. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Regenerx Biopharmaceuticals and its competitors.
Is Regenerx Biopharmaceuticals' Accounts Payable too high?
Regenerx Biopharmaceuticals' current Accounts Payable is $0.04 Mil.
How does Regenerx Biopharmaceuticals' Accounts Payable compare to MYMX and RGMP?
Regenerx Biopharmaceuticals' Accounts Payable of $0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Regenerx Biopharmaceuticals and its competitors. Regenerx Biopharmaceuticals's current Accounts Payable is $0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerx Biopharmaceuticals stock overvalued right now?
Regenerx Biopharmaceuticals (RGRX) has a current Accounts Payable of $0.04 Mil. The current Accounts Payable is $0.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Regenerx Biopharmaceuticals (RGRX), the current Accounts Payable is $0.04 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerx Biopharmaceuticals Business Description

Address 15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.